Mid-Term Outcomes and Echocardiographic Predictors of TTVR: Insights from the TRAVEL Study
In this LuX-Valve TTVR cohort, 30-day MAEs mainly reflected perioperative or device-related complications rather than a direct signal of baseline RV dysfunction or remodeling; LuX-Valve implantation showed favorable mid-term survival and clinically meaningful procedural effectiveness.